Dr. MiltieAtlas by Dr. Miltie™Healthcare Grant Intelligence
Open - rolling; next deadline November 6, 2026Atlas Opportunity Score 99/100
FL-DOH-FCIF-FY27-2026FloridaFlorida Department of HealthHealth SystemHealthcare ProviderHospitalCancer Research & Clinical TrialsCancer ScreeningClinical Quality Improvement

Florida Cancer Innovation Fund FY 2026-27

Florida has approximately $70 million available through the FY 2026-27 Florida Cancer Innovation Fund for high-impact cancer innovation, clinical and translational work, implementation, technology, screening, nutrition-based prevention and related initiatives. Eligible Florida-based organizations may request up to $2 million; the first rolling application period closes September 25, 2026 at 11:59 PM ET.

FundingApproximately $70 million available statewide; applicants may request up to $2 million.
DeadlinePeriod 1: September 25, 2026 at 11:59 PM ET. Period 2: November 6, 2026 at 11:59 PM ET. Period 3: December 18, 2026. The September 8, 2026 Florida DOH Q&A confirms these rolling deadlines and states that the FY 2026-27 FOA governs over the older conflicting Application Process webpage.
Last verifiedOctober 7, 2026
Required next actionUse the September 8, 2026 Florida DOH Q&A, FY 2026-27 FOA, and current FCIF portal as controlling guidance. Period 2 is active through November 6, 2026 and Period 3 runs November 7 through December 18, 2026. Confirm statutory eligibility, select the correct grant category, prepare the required work plan with measurable deliverables and success metrics, and submit through the portal during the applicable rolling period. Equipment above $5,000 requires additional Department review, and any subcontract requires pre-approval and narrative justification.

Broad Eligibility

Florida-based licensed or certified healthcare providers, facilities and entities meeting at least one qualifying criterion in the FOA, including certain rural or underserved hospitals, rural hospitals, Critical Access Hospitals, pediatric specialty hospitals, oncology clinics or treatment facilities, low- or no-cost cancer screening providers, accredited cancer programs, biomedical research organizations and institutions training cancer-screening, diagnostic or treatment practitioners.

Atlas Analysis

Florida FY 2026-27 Cancer Innovation Fund opportunity for Florida-based applicants. Approximately $70,000,000 is available across the cycle, with requests up to $2,000,000. The current application process uses three rolling periods. Period 1 has closed; later periods remain open. Projects are expected to be one-year, high-impact, interdisciplinary efforts with specific measurable deliverables and a clear pathway to practical impact.

Current status: Active. Florida Department of Health released the FY 2026-27 Cancer Innovation Fund Funding Opportunity Announcement on August 14, 2026, with approximately $70 million available and awards of up to $2 million for 12-month cancer innovation projects.

Current application window: Period 1 applications are due September 25, 2026 at 11:59 PM ET. Additional review periods close November 6 and December 18, 2026. Florida DOH published the FY 2026-27 Q&A on September 1 and updated it September 8; the Q&A confirms the September 25 Period 1 deadline and clarifies budget and application rules.

Source reconciliation: Atlas is using the controlling FY 2026-27 FOA and the live portal dashboard for the current dates. A secondary portal application-process page still displays older August 26 and October 22 period dates and should not be used as the controlling deadline source. The FOA’s key-points section and portal dashboard both identify September 25, November 6, and December 18 as the three FY 2026-27 review cutoffs. The detailed Period 3 paragraph in the FOA contains an internal inconsistency by stating that applications accepted November 7 through December 18 are received by 11:59 p.m. ET on November 7; Atlas therefore requires a source recheck before any Period 3 deadline-dependent action.

Eligible applicants: Florida-based licensed or certified healthcare providers, facilities, or entities meeting the statutory cancer-program criteria described in the FOA, including qualifying cancer treatment, screening, research, clinical education, rural hospital, and related organizations. Collaborations are encouraged.

Allowable commercial pathway: The FOA permits subcontracted services when justified and pre-approved in the Public Health Research Program Budget Template, and budgets may include personnel, equipment, supplies, and technical support. Equipment above $5,000 requires additional Florida Department of Health review and approval. Vehicles, construction, renovation, and remodeling are not allowable.

N9+ Fit: 64/100 — CONDITIONAL. Dr. Miltie is not established as a direct eligible applicant under the FOA. The strongest defensible pathway is vendor/subcontractor participation through an eligible Florida cancer organization, positioning N9+ as remote clinical examination technology and technical support within an integrated cancer care, decentralized care, underserved-access, rural-access, or implementation project. Florida has previously funded a Cancer CARE Beyond Walls model using digital technology and remote patient monitoring to bring portions of cancer care into patients’ homes, which strengthens the fit for a carefully designed remote-care proposal.

Atlas capture priority: High. The combination of explicit technology/equipment/technical-support allowability, subcontracting, scalable care-model objectives, and prior state investment in remote cancer care supports immediate partner-target identification and a grant-specific N9+ capture strategy. No applicant-facing outreach should occur without organization-specific eligibility verification, a complete package, duplicate-send review, and the required pre-send QA.

Source verificationOfficial government source · cancerinnovation.floridahealth.govAtlas last verified this record October 7, 2026. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗